Search
for
Sort by
Research 691–720 of 1000+
- Multiomics-empowered Deep Phenotyping of Ulcerative Colitis Identifies Biomarker Signatures Reporting Functional Remission States
- Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System
- The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System
- A pharmacovigilance study of drug‐reduced male semen quality based on the Food and Drug Administration adverse event reporting system database
- Platelet-Rich Plasma for Urologic Conditions: An Early Call for Composition Reporting
- Moth eaten alopecia as a manifestation of group of skin diseases: Reporting a series of 100 cases
- 1452 DETECTION RATE OF CLINICALLY INSIGNIFICANT PROSTATE CANCER INCREASES WITH REPEATING PROSTATE BIOPSIES
- Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review
- Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database
- 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)
- Novel modulatory effects of neurosteroids and benzodiazepines on excitatory and inhibitory neurons excitability: a multi-electrode array recording study
- Analysis of the relationship between the mutation site of the SLC39A4 gene and acrodermatitis enteropathica by reporting a rare Chinese twin: a case report and review of the literature
- Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
- Cyclic combing of untreated and bleached human hair: Analysis of the time‐dependent breakage of hair through recording the formation of fibre fragments
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Response to “The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System”
- Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
- Implementing patient safety and quality improvement in dermatology. Part 1: Patient safety science
- Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- A Gender Hypothesis of sex disparities in adverse drug events
- 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review
- Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.
- Post-Exposure Syndromes as State-Space Trapping: A set-theoretic perspective on PSSD and the post-exposure family.
- Supplementary Material for: Finasteride and Suicide: A Postmarketing Case Series
- Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report
- How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects
- Controversies: Is Finasteride Safety Data Adequately Reported in Published Trials?